Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides

Takuma Shirasaka, Mark F. Kavlick, Takamasa Ueno, Wen Yi Gao, Eiji Kojima, Maria L Alcaide, Sudhichai Chokekijchai, Birgit M. Roy, Edward Arnold, Robert Yarchoan, Hiroaki Mitsuya

Research output: Contribution to journalArticle

354 Citations (Scopus)

Abstract

A set of mutations [Ala-62 → Val(A62V), V751, F77L, F116Y, and Q151M] in the polymerase domain of reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) confers on the virus a reduced sensitivity to multiple antiretroviral dideoxynucleosides and has been seen in HIV-1 variants isolated from patients receiving combination chemotherapy with 3'-azido-3'- deoxythymidine (AZT) plus 2',3'-dideoxycytidine (ddC) or 2',3'-dideoxyinosine (ddI). The IC50 values of AZT, ddC, ddI, 2',3'-dideoxyguanosine, and 2',3'- didehydro-3'-deoxythymidine against an infectious clone constructed to include the five mutations were significantly higher than those of a wild- type infectious clone. The K(i) value for AZT 5'-triphosphate determined for the virus-associated RT from a posttherapy strain was 35-fold higher than that of RT from a pretherapy strain. Detailed analysis of HIV-1 strains isolated at various times during therapy showed that the Q151M mutation developed first in vivo, at the time when the viremia level suddenly increased, followed by the F116Y and F77L mutations. All five mutations ultimately developed, and the viremia level rose even further. Analyses based on the three-dimensional structure of HIV-1 RT suggest that the positions where at least several of the five mutations occur are located in close proximity to the proposed dNTP-binding site of RT and the first nucleotide position of the single-stranded template.

Original languageEnglish
Pages (from-to)2398-2402
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume92
Issue number6
DOIs
StatePublished - Mar 14 1995
Externally publishedYes

Fingerprint

Dideoxynucleosides
HIV-1
Mutation
RNA-Directed DNA Polymerase
Zalcitabine
Didanosine
Viremia
Therapeutics
Clone Cells
Stavudine
Viruses
Zidovudine
Combination Drug Therapy
Inhibitory Concentration 50
Nucleotides
Binding Sites

Keywords

  • dNTP-binding site
  • multidrug resistance
  • reverse transcriptase

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. / Shirasaka, Takuma; Kavlick, Mark F.; Ueno, Takamasa; Gao, Wen Yi; Kojima, Eiji; Alcaide, Maria L; Chokekijchai, Sudhichai; Roy, Birgit M.; Arnold, Edward; Yarchoan, Robert; Mitsuya, Hiroaki.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 92, No. 6, 14.03.1995, p. 2398-2402.

Research output: Contribution to journalArticle

Shirasaka, Takuma ; Kavlick, Mark F. ; Ueno, Takamasa ; Gao, Wen Yi ; Kojima, Eiji ; Alcaide, Maria L ; Chokekijchai, Sudhichai ; Roy, Birgit M. ; Arnold, Edward ; Yarchoan, Robert ; Mitsuya, Hiroaki. / Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. In: Proceedings of the National Academy of Sciences of the United States of America. 1995 ; Vol. 92, No. 6. pp. 2398-2402.
@article{e5aed044327b46e887584dfbf5cfa3bb,
title = "Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides",
abstract = "A set of mutations [Ala-62 → Val(A62V), V751, F77L, F116Y, and Q151M] in the polymerase domain of reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) confers on the virus a reduced sensitivity to multiple antiretroviral dideoxynucleosides and has been seen in HIV-1 variants isolated from patients receiving combination chemotherapy with 3'-azido-3'- deoxythymidine (AZT) plus 2',3'-dideoxycytidine (ddC) or 2',3'-dideoxyinosine (ddI). The IC50 values of AZT, ddC, ddI, 2',3'-dideoxyguanosine, and 2',3'- didehydro-3'-deoxythymidine against an infectious clone constructed to include the five mutations were significantly higher than those of a wild- type infectious clone. The K(i) value for AZT 5'-triphosphate determined for the virus-associated RT from a posttherapy strain was 35-fold higher than that of RT from a pretherapy strain. Detailed analysis of HIV-1 strains isolated at various times during therapy showed that the Q151M mutation developed first in vivo, at the time when the viremia level suddenly increased, followed by the F116Y and F77L mutations. All five mutations ultimately developed, and the viremia level rose even further. Analyses based on the three-dimensional structure of HIV-1 RT suggest that the positions where at least several of the five mutations occur are located in close proximity to the proposed dNTP-binding site of RT and the first nucleotide position of the single-stranded template.",
keywords = "dNTP-binding site, multidrug resistance, reverse transcriptase",
author = "Takuma Shirasaka and Kavlick, {Mark F.} and Takamasa Ueno and Gao, {Wen Yi} and Eiji Kojima and Alcaide, {Maria L} and Sudhichai Chokekijchai and Roy, {Birgit M.} and Edward Arnold and Robert Yarchoan and Hiroaki Mitsuya",
year = "1995",
month = "3",
day = "14",
doi = "10.1073/pnas.92.6.2398",
language = "English",
volume = "92",
pages = "2398--2402",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "6",

}

TY - JOUR

T1 - Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides

AU - Shirasaka, Takuma

AU - Kavlick, Mark F.

AU - Ueno, Takamasa

AU - Gao, Wen Yi

AU - Kojima, Eiji

AU - Alcaide, Maria L

AU - Chokekijchai, Sudhichai

AU - Roy, Birgit M.

AU - Arnold, Edward

AU - Yarchoan, Robert

AU - Mitsuya, Hiroaki

PY - 1995/3/14

Y1 - 1995/3/14

N2 - A set of mutations [Ala-62 → Val(A62V), V751, F77L, F116Y, and Q151M] in the polymerase domain of reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) confers on the virus a reduced sensitivity to multiple antiretroviral dideoxynucleosides and has been seen in HIV-1 variants isolated from patients receiving combination chemotherapy with 3'-azido-3'- deoxythymidine (AZT) plus 2',3'-dideoxycytidine (ddC) or 2',3'-dideoxyinosine (ddI). The IC50 values of AZT, ddC, ddI, 2',3'-dideoxyguanosine, and 2',3'- didehydro-3'-deoxythymidine against an infectious clone constructed to include the five mutations were significantly higher than those of a wild- type infectious clone. The K(i) value for AZT 5'-triphosphate determined for the virus-associated RT from a posttherapy strain was 35-fold higher than that of RT from a pretherapy strain. Detailed analysis of HIV-1 strains isolated at various times during therapy showed that the Q151M mutation developed first in vivo, at the time when the viremia level suddenly increased, followed by the F116Y and F77L mutations. All five mutations ultimately developed, and the viremia level rose even further. Analyses based on the three-dimensional structure of HIV-1 RT suggest that the positions where at least several of the five mutations occur are located in close proximity to the proposed dNTP-binding site of RT and the first nucleotide position of the single-stranded template.

AB - A set of mutations [Ala-62 → Val(A62V), V751, F77L, F116Y, and Q151M] in the polymerase domain of reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) confers on the virus a reduced sensitivity to multiple antiretroviral dideoxynucleosides and has been seen in HIV-1 variants isolated from patients receiving combination chemotherapy with 3'-azido-3'- deoxythymidine (AZT) plus 2',3'-dideoxycytidine (ddC) or 2',3'-dideoxyinosine (ddI). The IC50 values of AZT, ddC, ddI, 2',3'-dideoxyguanosine, and 2',3'- didehydro-3'-deoxythymidine against an infectious clone constructed to include the five mutations were significantly higher than those of a wild- type infectious clone. The K(i) value for AZT 5'-triphosphate determined for the virus-associated RT from a posttherapy strain was 35-fold higher than that of RT from a pretherapy strain. Detailed analysis of HIV-1 strains isolated at various times during therapy showed that the Q151M mutation developed first in vivo, at the time when the viremia level suddenly increased, followed by the F116Y and F77L mutations. All five mutations ultimately developed, and the viremia level rose even further. Analyses based on the three-dimensional structure of HIV-1 RT suggest that the positions where at least several of the five mutations occur are located in close proximity to the proposed dNTP-binding site of RT and the first nucleotide position of the single-stranded template.

KW - dNTP-binding site

KW - multidrug resistance

KW - reverse transcriptase

UR - http://www.scopus.com/inward/record.url?scp=0028940084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028940084&partnerID=8YFLogxK

U2 - 10.1073/pnas.92.6.2398

DO - 10.1073/pnas.92.6.2398

M3 - Article

C2 - 7534421

AN - SCOPUS:0028940084

VL - 92

SP - 2398

EP - 2402

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 6

ER -